Genesis Electrical Impedance Tomography (EIT): A Preliminary Study
Launched by UNIVERSITY OF COLORADO, DENVER · Jan 4, 2019
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
The Genesis Electrical Impedance Tomography (EIT) study is looking at a new imaging system that helps doctors see how well children's lungs are working without using any radiation. This trial focuses on children with various respiratory conditions, including premature infants suffering from bronchopulmonary dysplasia (BPD) and those with chronic respiratory issues related to neuromuscular diseases. The study also includes healthy children to compare results. If you are between 2 weeks and 40 years old and meet certain health criteria, you might be eligible to participate in this research.
Participants can expect to have electrodes placed on their chest to gather data about lung function. The study is currently recruiting individuals, so if you or someone you know is interested, it’s a good idea to reach out. However, some individuals will not be able to participate, including those under 2 weeks old or those with specific health issues like severe congenital heart disease or any conditions that would make it hard to place the electrodes. This trial could help improve our understanding of lung health in children and lead to better treatments in the future.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 2 weeks old - 40 years old
- • Premature infants with current age \>2 weeks with a confirmed diagnosis of BPD based on NIH criteria
- • Or Chronic respiratory disease due to underlying neuromuscular disease
- • Or confirmed neuromuscular disease with an echo completed within the preceding 12 months of study participation of DMD or other diagnoses associated with mild cardiomyopathy.
- • have had a VQ scan
- • will be undergoing cardiac catherization for for pulmonary vein stenosis, pulmonary hypertension and/or pulmonary artery stenosis
- • Or healthy controls
- Exclusion Criteria:
- • \<2 weeks of age
- • Congenital diaphragmatic hernia
- • Severe congenital heart disease
- • Significant genetic abnoralities
- • Anything that interferes with lead placement on the chest wall
- • Unwilling/refusal to sign consent
- • Pregnant or lactating
- • Pacemaker of other surgical implant and spinal implant (causes noise in the data)
- • Moderate to severe cardiomyopathy
- • Patients with temporary cognitive disability due to illness
About University Of Colorado, Denver
The University of Colorado, Denver, is a leading academic institution dedicated to advancing medical research and improving healthcare outcomes. With a strong emphasis on innovation and collaboration, the university conducts a diverse range of clinical trials aimed at addressing critical health challenges. Its research initiatives are supported by a multidisciplinary team of experts, state-of-the-art facilities, and a commitment to ethical standards and patient safety. By fostering partnerships with local and global communities, the University of Colorado, Denver, strives to translate scientific discoveries into meaningful advancements in clinical practice and public health.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Aurora, Colorado, United States
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials